Dr. Yang is an author of 17 peer-reviewed publications (7 first author papers and 1 corresponding author paper) with 1 US patent. Her recent study on APE/Ref-1 has been funded with a Mentored Clinical Scientist Research Career Development Award (K08) by the National Cancer Institute (NCI).
The aberrant pathways in cancer cells may be utilized for developing targeted therapeutics. Dr. Yang’s research is focused on identifying effective novel targets and approaches for melanoma therapy and prevention, especially through the extensive mechanistic studies of abnormal reducing-oxidative (redox)-regulated signal pathways in melanoma compared to normal melanocytes. Her current ongoing projects include developing small molecules targeting APE/Ref-1- and nNOS-mediated signal pathways and the lead compounds exhibited promising anti-melanoma activities both in vitro and in vivo.
In addition, Dr. Yang’s group is also interested in translational research in pediatric pharmacology focusing on the mechanisms of drug action, clinical response, and medication safety in children at various development stages.